Bristol Myers Squibb

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Bristol Myers Squibb
TickerBMY
CIK #0000014272
CUSIP110122108
SectorLife Sciences
IndustryPharmaceutical Preparations
Phone2125464000
Address345 Park Ave
New York, NY 10154
Source [EDGAR]
Market Cap, 13F ($BB)
1209672482402011201320152018
Business

On November 20, 2019, we completed our acquisition of Celgene and, as a result, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company. Under the terms of the transaction, Celgene shareholders received one share of Bristol-Myers Squibb common stock and $50.00 in cash for each share of Celgene common stock held by them. Celgene shareholders also received one contingent value right (the "CVR") representing the right to receive $9.00 in cash, which is subject to the achievement of future regulatory milestones, for each share of Celgene common stock. We funded the cash portion of the merger consideration with available cash, which included $18.8 billion of net proceeds raised in the May 2019 issuance of new notes and $8 billion of borrowings under the term loan established in January 2019 in connection with the acquisition. Based on the closing share price of our common stock on November 20, 2019, the aggregate purchase price was approximately $80.3 billion, including approximately $35.7 billion in cash and approximately $40.4 billion in Bristol-Myers Squibb common stock.

To allow the acquisition by Bristol-Myers Squibb to close on a timely basis in light of concerns expressed by the Federal Trade Commission (the "FTC"), Celgene entered into a purchase agreement with Amgen on August 25, 2019 under which Amgen would acquire the global rights to Otezla* (apremilast) for $13.4 billion. In connection with the divestiture and Celgene entering into the purchase agreement, we entered into a guarantee with Amgen under which we agreed to guarantee the full payment and performance of Celgene's obligations under the purchase agreement. On November 15, 2019, the FTC accepted the consent order for public comment, which allowed the acquisition of Celgene to proceed subject to certain conditions, including the completion of the divestiture of Otezla* to Amgen. On November 21, 2019, the divestiture of Otezla* was completed.

We continue to operate in one segment-Biopharmaceuticals after our acquisition of Celgene. For additional information about our business segment, refer to "Item 8. Financial Statements and Supplementary Data-Note 1. Accounting Policies and Recently Issued Accounting Standards." We believe that our combination with Celgene will enable us to create a leading biopharmaceutical company that is well-positioned to address the needs of patients with cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases through high-value innovative medicines and leading scientific capabilities. Our principal strategy is to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology (both solid tumors and hematology), immunology, cardiovascular and fibrosis. Our new four strategic priorities as a combined company are to drive enterprise performance, maximize the value of our commercial portfolio, ensure the long-term sustainability of our pipeline through combined internal and external innovation and establish our new culture and embed our people strategy. While we are committed to reducing the debt that we incurred in connection with the Celgene transaction, we plan to remain focused on broadening our portfolio of marketed medicines and pipeline assets. For a further discussion of our strategy initiatives, refer to "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Strategy."

CIK Filing 2011 - 2021
[0000014272] 10-K
[0000014272] 10-Q
[0000014272] 3
[0000014272] 4
[0000014272] 5
[0000014272] 8-K
[0000014272] SC 13D
[0000014272] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Wellington Management Group LLP Bristol Myers Squibb Co [2019-05-10] 7.41
Wellington Management Group LLP Bristol Myers Squibb Co [2019-02-27] 7.7
Bristol Myers Squibb Co Uniqure NV [2015-06-22] 4.9
Wellington Management Group LLP Bristol Myers Squibb Co [2015-02-12] 8.15
Vanguard Group Inc Bristol Myers Squibb Co [2015-02-11] 5.5
Bristol Myers Squibb Co KYTO Biopharma Inc [2014-10-06] 10.0
Bristol Myers Squibb Co Alder Biopharmaceuticals Inc [2014-05-19] 5.35
Bristol Myers Squibb Co Inhibitex Inc [2012-01-13] 14.0
Form 3/4/5 Filer 2011-2021
Vessey Rupert
EID Joseph
Boerner Christopher S
Elkins David V
Ahmed Nadim
von Autenried Paul
Dubow Adam
Bertolini Robert J
Rice Derica W
Bonney Michael W
Storch Gerald L
Samuels Theodore R II
Haller Julia A
Vousden Karen H
Paliwal Dinesh C
Yale Phyllis R
Price Paula A
Emmens Matthew
Arduini Peter J
Santiago Karen Murphy
Caforio Giovanni
Leung Sandra
Acceleron Pharma Inc
Celgene Corp /DE/
Grobstein Michael
LACY Alan J
Hirawat Samit
Schmukler Louis S
MILY Elizabeth
Judge Ann Powell
Metcalfe Kathryn
Elicker John E
Bancroft Charles A
Sato Vicki L
Biondi Paul
Lynch Thomas J Jr
Baselga Jose
Gordon Murdo
Caldarella Joseph C
Nielsen Anne
Andreotti Lamberto
BLIN Emmanuel
CUSS Francis M
West TOGO D Jr
Glimeher Laurie H
Campbell Lewis B
Cornelius James M
MOED Samuel J
Medarex Inc
KYTO Biopharma Inc
Daniels Brian
Heller Frances K
Sigal Elliot
Cazala Beatrice J
Williams R Sanders
Freeh Louis J
Celentano John E
Inhibitex Inc
INTA Acquisition Corp
MM Shares Owned of 1,632.2 MM Total
Firm Period DFND Voting Shares
Vanguard Group Inc [2020-09-30] SOLE 0.0 189.7
BlackRock Inc. [2020-09-30] SOLE 139.8 162.4
State Street Corp [2020-09-30] DFND 84.4 97.5
JPMorgan Chase & Co [2020-09-30] DFND 58.7 63.8
FMR LLC [2020-09-30] DFND 6.3 62.6
Wellington Management Group LLP [2020-09-30] DFND 0.0 54.0
Geode Capital Management LLC [2020-09-30] DFND 33.6 33.7
Bank of America Corp /DE/ [2020-09-30] DFND 5.8 33.1
Renaissance Technologies LLC [2020-09-30] SOLE 30.2 30.6
Berkshire Hathaway Inc [2020-09-30] DFND 30.0 30.0
Ameriprise Financial Inc [2020-09-30] DFND 0.0 29.4
Northern Trust Corp [2020-09-30] DFND 9.7 27.4
Dodge & Cox [2020-09-30] SOLE 25.9 27.2
Bank of New York Mellon Corp [2020-09-30] DFND 23.0 27.2
Janus Henderson Group PLC [2020-09-30] DFND 0.0 23.7
Invesco Ltd. [2020-09-30] DFND 0.0 21.2
Morgan Stanley [2020-09-30] DFND 1.9 21.2
PRIMECAP Management Co/Ca/ [2020-09-30] SOLE 19.1 20.0
Legal & General Group Plc [2020-09-30] DFND 10.3 14.3
Loomis Sayles & Co L P [2020-09-30] DFND 13.4 13.4
Nordea Investment Management AB [2020-09-30] SOLE 1.3 13.2
Nuveen Asset Management LLC [2020-09-30] DFND 13.1 13.2
Wells Fargo & Co/Mn [2020-09-30] DFND 10.5 12.9
LSV Asset Management [2020-09-30] SOLE 7.7 11.6
Capital World Investors [2020-09-30] DFND 11.0 11.0
Citadel Advisors LLC [2020-09-30] DFND 10.7 10.7
Schwab Charles Investment Management Inc [2020-09-30] SOLE 10.5 10.5
Vanguard Group Inc [2020-09-30] DFND 0.0 10.3
Susquehanna International Group LLP [2020-09-30] DFND 0.1 10.1
Sumitomo Mitsui Trust Holdings, Inc. [2020-09-30] DFND 9.7 9.7
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com